Levilimab
Anti-IL-6 monoclonal antibody
Pharmaceutical compound
Levilimab is an anti-IL-6 monoclonal antibody initially developed to treat rheumatoid arthritis . In 2020, it was approved as a treatment for COVID-19 in Russia.[ 1] [ 2] [ 3]
References
^ Harrison, Charlotte (1 August 2020). "Focus shifts to antibody cocktails for COVID-19 cytokine storm" . Nature Biotechnology . 38 (8): 905– 908. doi :10.1038/s41587-020-0634-9 ISSN 1546-1696 . PMID 32760027 . S2CID 220980850 . ^ Gomon, Y. M.; Strizheletsky, V. V.; Ivanov, I. G.; Balykina, Y. E.; Ermolyev, M. V.; Kolbin, A. S.; Livshits, M. V.; Usmanova, T. A.; Fakhrutdinova, A. M.; Konstantinova, Y. S.; Gubanov, A. P. (2023). "Efficiency of Levilimab in patients with moderate and severe COVID-19" . Farmakoekonomika (in Russian). pp. 36– 47. Retrieved 4 November 2023 . ^ Lomakin, Nikita V.; Bakirov, Bulat A.; Protsenko, Denis N.; Mazurov, Vadim I.; Musaev, Gaziyavdibir H.; Moiseeva, Olga M.; Pasechnik, Elena S.; Popov, Vladimir V.; Smolyarchuk, Elena A.; Gordeev, Ivan G.; Gilyarov, Mikhail Yu; Fomina, Darya S.; Seleznev, Anton I.; Linkova, Yulia N.; Dokukina, Ekaterina A.; Eremeeva, Anna V.; Pukhtinskaia, Polina S.; Morozova, Maria A.; Zinkina-Orikhan, Arina V.; Lutckii, Anton A. (December 2021). "The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study" . Inflammation Research . 70 (10– 12): 1233– 1246. doi :10.1007/s00011-021-01507-5 . ISSN 1420-908X . PMC 8479713 PMID 34586459 .
